Table 1 Baseline patient characteristics
Baseline Cohort (N = 72) | High neutrophil count* (N = 51) | Low T cell count** (N = 19) | Low B cell count*** (N = 21) | High NLR**** (N = 34) | |
|---|---|---|---|---|---|
Median age | 69 | 68 | 71 | 72 | 68 |
(range) | (47–92) | (47–92) | (50–84) | (59–92) | (47–92) |
P value | 0.852 | 0.248 | 0.116 | 0.657 | |
Median CA-125 kU/L | 332 | 488 | 330 | 616 | 487 |
(range) | (6–30,072) | (6–30,072) | (11–30,072) | (13–10,325) | (6–30,072) |
P value | 0.411 | 0.443 | 0.443 | 0.443 | |
Histology | |||||
High-grade serous carcinoma | 61 (84%) | 45 (88%) | 18 (95%) | 18 (85%) | 31 (88%) |
Low-grade serous carcinoma | 4 (6%) | 3 (6%) | 0 (0%) | 0 (0%) | 1 (3%) |
Endometrioid | 4 (6%) | 2 (4%) | 0 (0%) | 2 (10%) | 2 (6%) |
Mucinous | 3 (4%) | 1 (2%) | 1 (5%) | 1 (5%) | 1 (3%) |
P value | 0.366 | 0.486 | 0.203 | 0.614 | |
Previous lines of chemotherapy | |||||
1 | 32 (44%) | 22 (43%) | 4 (21%) | 4 (19%) | 11 (32%) |
2–3 | 31 (43%) | 23 (45%) | 12 (63%) | 15 (71%) | 19 (54%) |
4–5 | 9 (13%) | 6 (12%) | 3 (16%) | 2 (10%) | 5 (14%) |
P value | 0.391 | 0.068 | 0.011 | 0.122 | |
Platinum sensitive | |||||
No | 48 (67%) | 33 (65%) | 14 (74%) | 15 (71%) | 25 (71%) |
Yes | 24 (33%) | 18 (35%) | 5 (26%) | 6 (29%) | 10 (29%) |
P value | 0.582 | 0.446 | 0.579 | 0.395 | |
Performance status | |||||
0–1 | 46 (64%) | 31 (61%) | 11 (58%) | 14 (66%) | 21 (60%) |
2 | 26 (36%) | 20 (39%) | 8 (42%) | 7 (34%) | 14 (40%) |
P value | 0.393 | 0.532 | 0.749 | 0.509 | |
Treatment regimen | |||||
Carboplatin | 10 (14%) | 9 (18%) | 3 (16%) | 4 (19%) | 8 (23%) |
Carboplatin + lipos. Dox. | 13 (18%) | 8 (16%) | 2 (11%) | 2 (10%) | 2 (6%) |
Carboplatin + paclitaxel | 1 (1%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) |
Liposomal doxorubicin | 14 (20%) | 10 (19%)) | 4 (21%) | 2 (10%) | 8 (23%) |
Topotecan | 16 (22%) | 11 (21%) | 6 (31%) | 5 (23%) | 9 (25%) |
Treosulfan | 12 (17%) | 8 (16%) | 2 (11%) | 5 (23%) | 5 (14%) |
Paclitaxel | 2 (3%) | 2 (4%) | 1 (5%) | 1 (5%) | 1 (3%) |
Gemcitabine | 2 (3%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) |
Vinorelbine | 1 (1%) | 1 (2%) | 1 (5%) | 1 (5%) | 1 (3%) |
Bevacizumab | 1 (1%) | 0 (0%) | 0 (0%) | 1 (5%) | 1 (3%) |
P value | 0.642 | 0.579 | 0.251 | 0.062 | |
Maintenance treatment# | |||||
Bevacizumab | 8 (11%) | 4 (8%) | 2 (11%) | 1 (5%) | 2 (6%) |
Olaparib | 3 (4%) | 3 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
P value | 0.125 | 0.301 | 0.490 | 0.301 | |